Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
1999-04-21
2001-10-16
Jones, W. Gary (Department: 1655)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C435S005000, C435S006120, C435S091100, C435S091200, C530S317000
Reexamination Certificate
active
06303576
ABSTRACT:
TECHNICAL FIELD
The present invention relates generally to compounds and methods for use in modulating &bgr;-catenin mediated gene expression and cellular differentiation. The invention is more specifically related to modulating agents capable of affecting the interaction between &bgr;-catenin and transcription factors, and to therapeutic methods employing such agents.
BACKGROUND OF THE INVENTION
&bgr;-catenin is a cytoplasmic protein that is critical for classical cadherin-mediated intercellular adhesion. Inside the cell, a &bgr;-catenin/&agr;-catenin complex interacts with the second cytoplasmic domain (CP2) of the classical cadherins. In the absence of this &bgr;-catenin/&agr;-catenin complex, the classical cadherins cannot promote cell adhesion (see Wheelock et al.,
Current Topics in Membranes
43:169-185, 1996).
In addition to its role in cell adhesion, &bgr;-catenin is also a key component of certain cellular signaling pathways, leading to activation of gene expression and a variety of developmental and disease processes, such as differentiation, cancer and Alzheimer's disease. In particular, &bgr;-catenin functions in Wnt-mediated signaling, associating with LEF-1/TCF DNA binding proteins to form a transcription factor (see Willert and Nusse,
Genetics and Development
8:95-102, 1998). &bgr;-catenin-mediated signaling is involved in a variety of developmental processes, including cellular differentiation. For example, skin cells expressing a stabilized form of &bgr;-catenin display increased hair growth (Gat et al.,
Cell
95:605-614, 1998; Ono et al.,
Cell
95:575-578, 1998). Thus, therapies based on modulating &bgr;-catenin mediated gene expression have potential for altering cell differentiation and, in certain instances, hair growth. Such therapies could further be used in the treatment of cancer and Alzheimer's disease. However, there are presently no available therapies for inhibiting &bgr;-catenin-mediated signaling.
Accordingly, there is a need in the art for improved methods for modulating &bgr;-catenin-mediated signal transduction and cellular differentiation. The present invention fulfills this need and further provides other related advantages.
SUMMARY OF THE INVENTION
The present invention provides methods for inhibiting &bgr;-catenin mediated gene transcription and cellular differentiation. Within certain aspects, the present invention provides modulating agents comprising one or more of: (a) the amino acid sequence LXXLL (SEQ ID NO:1); or (b) a peptide analogue or peptidomimetic of the amino acid sequence LXXLL (SEQ ID NO:1). Within certain embodiments, the modulating agent comprises the sequence LXXLL (SEQ ID NO:1) within a linear peptide or a cyclic peptide ring. Such modulating agents may, within certain embodiments, comprise a linear or cyclic peptide ranging from 3 to 16 amino acid residues in length. A modulating agent may further comprise an internalization moiety, such as an internalization sequence covalently linked to the modulating agent, a liposome that encapsulates the modulating agent or an antibody or ligand that binds to a cell surface receptor. Within further embodiments, any of the above modulating agents may be linked to a targeting agent and/or a drug.
Within other aspects, the present invention provides pharmaceutical compositions comprising a modulating agent as described above, in combination with a pharmaceutically acceptable carrier.
Within further related aspects, the present invention provides methods for modulating the activation of &bgr;-catenin mediated gene transcription in a cell, comprising contacting a cell with a modulating agent as described above.
Within further related aspects, the present invention provides methods for modulating differentiation of a cell, comprising contacting a cell with a modulating agent as described above.
In other aspects, methods are provided for modulating hair growth on a mammal, comprising administering to a mammal a modulating agent as described above. Such administration may be topical.
The present invention further provides, within other aspects, methods for treating cancer and/or inhibiting metastasis in a patient, comprising administering to a patient a modulating agent as described above.
Within further aspects, the present invention provides methods for inhibiting the development of Alzheimer's disease in a patient, comprising administering to a patient a modulating agent as described above.
The present invention further provides methods for modulating the activity of a retinoic acid receptor and/or androgen receptor in a cell, comprising contacting a cell with a modulating agent as described above.
These and other aspects of the invention will become evident upon reference to the following detailed description and attached drawings. All references disclosed herein are hereby incorporated by reference in their entirety as if each were individually noted for incorporation.
REFERENCES:
patent: 5652122 (1997-07-01), Frankel et al.
patent: 6031072 (2000-02-01), Blaschuk et al.
patent: WO98/45319 (1998-05-01), None
patent: 199 09 251 A1 (1999-08-01), None
patent: WO98/49561 (1998-05-01), None
patent: WO 98/45319 (1998-10-01), None
patent: WO 98/42296 (1998-10-01), None
patent: WO 98/49561 (1998-11-01), None
patent: WO 99/42481 (1999-08-01), None
Aberle et al., “&bgr;-catenin is a target for the ubiquitin-proteasome pathway,”The EMBO Journal 16(13): 3797-3804, 1997.
Easwaran et al., “The Ubiquitin/Proteosome Pathway And Apc Regulation Of &bgr;-Catenin/Lef Signaling,”Mol. Biol. Cell 9:p. 248a, Abstract No. 1440, 1998.
Gat et al., “De Novo Hair Follicel Morphogenesis and Hair Tumors in Mice Expressing a Truncated &bgr;-Catenin in Skin,”Cell 95: 605-614, 1998.
Oro and Scott, “Splitting Hairs: Dissecting Roles of Signaling Systems in Epidermal Development,”Cell 95: 575-578, 1998.
Orford et al., “Serine Phosporylation-regulated Ubiquitination and Degradation of &bgr;-Catenin,”The Journal of Biological Chemistry 272(40): 24735-24738, 1997.
Salomon et al., “Regulation of &bgr;-Catenin Levels and Localization by Overexpression of Plakoglobin and Inhibition of the Ubiquitin-Proteasome System,”The Journal of Cell Biology 139(5): 1325-1335, 1997.
Torchia et al., “The transcriptional co-activator p/CIP binds CBP and mediates nuclear-receptor function,”Nature 387: 677-684, 1997.
Willert and Nusse, “&bgr;-catenin: a key mediator of Wnt signaling,”Current Opinion in Genetics and Development 8: 95-102, 1998.
Zhang et al., “Destabilization of &bgr;-catenin by mutations in presenilin-1 potentiates neuronal apoptosis,”Nature 395: 698-702, 1998.
DE 19909251 A1, Derwent English Abstract, Accession No. 1999-470389/199940, Aug. 1999.
He et al., “Identification of c-MYC as a Target of the APC Pathway,”Science 281:1509-1512, Sep. 1998.
Heery et al., “A signature motif in transcriptional co-activators mediates binding to nuclear receptors,”Nature 387:733-736, Jun. 1997.
Hülsken et al., “E-Cadherin and APC Compete for the Interaction with &bgr;-Catenin and the Cytoskeleton,”J. Cell Biology 127(6):2061-2069, Dec. 1994.
Hülsken et al., “E-Cadherin amd APC Compete for the Interaction with &bgr;Catenin and the Cytoskeleton,” EMBL Sequence Database, Accession No. A38973, Jan. 1996.
Hülsken et al., “E-Cadherin and APC Compete for the Interation with &bgr;-Catenin and the Cytoskeleton,” EMBL Sequence Database, Accession No. P35222, Feb. 1994.
McCrea et al., “Plakoglobin and &bgr;-Catenin: Distinct But Closely Related,”Science 257:1142-1144, Aug. 1992.
Zhang et al., “Destabilization of &bgr;-Catenin by mutations in presenilin-1 potentiates neuronal apoptosis,”Nature 395:698-702, Oct. 1998.
Blaschuk Orest W.
Byers Stephen
Gour Barbara J.
Adherex Technologies Inc.
Jones W. Gary
Seed Intellectual Property Law Group PLLC
Taylor Janell E.
LandOfFree
Compounds and methods for modulating &bgr;-catenin mediated... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Compounds and methods for modulating &bgr;-catenin mediated..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Compounds and methods for modulating &bgr;-catenin mediated... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2611870